Telomere ShorteningNCT05598359
TA-65 and Aging Associated Microvascular Dysfunction
A study testing TA-65 in people with Telomere Shortening and Aging, run by Medical College of Wisconsin.
Trial summary
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Telomere Shortening, Aging, Vascular Diseases
- What is being tested?
- TA-65
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 180 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2027to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy Adults 18 - 35 and 65+ years of age
- Subjects with clinical diagnosis of CAD
Who cannot join
- 36-64 years of age without clinical diagnosis of CAD
- Self-reported habitual vigorous exercise (>20 min, 3 times per week, 1 yr)
- Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
- Heart Failure
- Renal Impairment
- >3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
Show all 24Show fewer
- Type 1 or type 2 diabetes
- Uncontrolled hypertension
- Current tobacco use or within last 6 months
- BMI > 35
- Hyperlipidemia
- Hypercholesterolemia
- Use of anti-coagulant drugs
- Use of anti-platelet drugs
- Erectile dysfunction medication in the past 6 months
- Use of topical/non-topical steroids in last 6 months
- Hormone replacement therapy (Post-Menopause or Gender Reassignment)
- History of retinopathy
- Documented neuromuscular disorders
- Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
- Pregnancy (young female subjects)
- Allergy to lidocaine
- Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
- Active COVID-19 or within the past 3 months
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.
Read the detailed description
The purpose of this clinical trial is to examine whether activation of autophagy with TA-65 which activates telomerase, improves microvascular function and blood pressure in an older population
- Conditions
- Telomere Shortening, Aging, Vascular Diseases
- Being tested
- TA-65, Placebo
- Medical subject headings
- Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TA-65Dietary supplement
TA-65 is a purified small molecule extracted from Astragalus root
PlaceboOther
Inactive formulation
| Study group | Role | What they receive |
|---|---|---|
| TA-65 | Experimental | TA-65 (250 U) taken once per day Receives: Dietary Supplement: TA-65 |
| Placebo | Placebo comparator | Placebo taken once per day Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis
Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME
Measured: 28 days
Secondary outcomes (1)
Systemic Blood Pressure
Brachial systolic, and diastolic blood pressure will be measured via standard brachial blood pressure cuff
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2022
- Study start1 Jan 2027 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Telomere ShorteningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical College of Wisconsin
- Sponsor type
- University, hospital or other
- Collaborators
- University of Louisville, Penn State University
- Responsible party
- Principal investigator, William Hughes, Medical College of Wisconsin
- Investigators
- Andreas Beyer, Ph.D., Principal investigator, Associate Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05598359
- Sponsor's protocol ID
- TA-65 and Vascular Aging
- Status last verified
- Apr 2026
- First submitted
- 18 Oct 2022
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TA-65 and Aging Associated Microvascular Dysfunction
- ClinicalTrials.gov ID
- NCT05598359
- Acronym / sponsor ID
- TA-65 and Vascular Aging
- Conditions
- Telomere Shortening, Aging, Vascular Diseases
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Medical College of WisconsinUniversity, hospital or other
- Collaborators
- University of Louisville, Penn State University
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 28 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.
Detailed description
The purpose of this clinical trial is to examine whether activation of autophagy with TA-65 which activates telomerase, improves microvascular function and blood pressure in an older population
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TA-65 | Experimental | Dietary Supplement: TA-65TA-65 (250 U) taken once per day |
| Placebo | Placebo comparator | Other: PlaceboPlacebo taken once per day |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Healthy Adults 18 - 35 and 65+ years of age
- Subjects with clinical diagnosis of CAD
Key exclusion criteria (24 listed)
- 36-64 years of age without clinical diagnosis of CAD
- Self-reported habitual vigorous exercise (>20 min, 3 times per week, 1 yr)
- Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
- Heart Failure
- Renal Impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TA-65TA-65 is a purified small molecule extracted from Astragalus root | Dietary supplement | TA-65 |
| PlaceboInactive formulation | Other | Placebo |
Primary outcome
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis
Time frame: 28 days
Cutaneous microvascular function measured via laser Doppler flowmetry coupled with intradermal microdialysis of non-specific nitric oxide synthase inhibitor, L-NAME
1 secondary outcome
Systemic Blood Pressure
Time frame: 28 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: Yes
Related trials for Telomere Shortening
Active, not recruiting
Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters
Aging, Obesity
Active, not recruitingPhase 1
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
Telomere Shortening, Bone Marrow Failure
Enrolling by invitationObservational study
Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over Time
Telomere Length in Healthy Controls
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Andreas Beyer, Ph.D. principal investigator
Associate Professor
Questions about this trial
What is this clinical trial studying?
A study testing TA-65 in people with Telomere Shortening and Aging, run by Medical College of Wisconsin.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andreas Beyer, Ph.D. (414-955-7514, abeyer@mcw.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nitric Oxide Mediated Endothelium-Dependent Vasodilation via Laser Doppler Flowmetry Coupled with Intradermal Microdialysis (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.